Articles related to LUNG CANCER

“Progress is sort of stepwise. How do we make things better? And what we see with FLAURA2 is that we do see an improvement in survival – a meaningful improvement in survival.” – Dr. Stephen Liu

Patients whose disease has progressed on osimertinib or other EGFR tyrosine kinase inhibitors (TKIs) without emergent T790M or other targetable alterations can receive platinum-based chemotherapy with or without amivantamab.

Subcutaneous administration of amivantamab demonstrated noninferiority to IV delivery while potentially offering enhanced patient convenience and reduced healthcare system burden.

Durvalumab consolidation therapy demonstrated unprecedented survival benefit in limited-stage SCLC, extending median overall survival by nearly two years compared to placebo.

AI-assisted diagnosis of lung cancer showed 87% sensitivity and 87% specificity in a meta-analysis, suggesting potential for improved accuracy in interpreting chest CT scans.

Osimertinib significantly improved progression-free survival in patients with unresectable stage III EGFR-mutant NSCLC after chemoradiotherapy, with a hazard ratio of 0.16 compared to placebo.